UNSPSC 51272103: Betoxycaine

This classification denotes an anesthetic agent with the molecular formula C19H32N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03DB58Y9DO, chemically known as ethanol, 2-(2-(diethylamino)ethoxy)-, 3-amino-4-butoxybenzoate but generally known as betoxycaine, which bears US NIH Compound Identifier 19668. Betoxycaine most often comes in base, q, and hydrochloride forms. European Medicines Agency schedules Betoxycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05807MIG.

UNSPSC 51272103 Betoxycaine is a Commodity code that captures pharmaceutical products and related medical supplies procured by state and local health agencies, though recent state and local solicitations under this code show substantial divergence from the specific chemical name—jurisdictions are instead buying naloxone and opioid antagonists, generic multi-source pharmaceuticals, and over-the-counter products through both direct procurement and cooperative purchasing arrangements. State and local issuing bodies range from county health departments and state health and human services agencies to multistate cooperative purchasing alliances coordinating procurement across participating jurisdictions. Seminole County, Florida, for instance, conducted an IFB in mid-2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county health facility; the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription programs and pharmacy benefit management alternatives; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon.

Activity spans Florida, Texas, and the upper Midwest as documented in recent postings. Cooperative purchasing vehicles dominate the landscape—MMCAP's RFP alone involves authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and extends across multiple states. Seminole County's IFB required electronic submission through e-Procurement and included FEMA compliance obligations. The MMCAP procurement, with proposals due March 26, 2026, demands cGMP and Drug Supply Chain Security Act certification, EDI capability, pricing submission via CSV-formatted Excel spreadsheets, commercial general liability of $5 million per occurrence, and performance penalties of $200 to $1,500 per violation. The Texas RFI, posted April 3, 2026, represents exploratory market research on direct contracting and outcomes-based pricing models rather than immediate competitive procurement. Vendors should expect two-year initial terms with optional renewals, administrative fees (MMCAP specifies 3 percent), and mandatory relationships with established pharmaceutical wholesalers and distribution channels.